{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/menorrhagia/management/management/","result":{"pageContext":{"chapter":{"id":"e30d2783-35fc-5470-9fb3-b8a643f83450","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field d11fc1e9-64f7-43a9-9a82-f5fbfb566b69 --><h2>Scenario: Management of menorrhagia (heavy menstrual bleeding)</h2><!-- end field d11fc1e9-64f7-43a9-9a82-f5fbfb566b69 -->","summary":"Covers the management of menorrhagia, including criteria for referral to secondary care.","htmlStringContent":"<!-- begin item 723b09b8-6a5c-4247-b5bb-f04b82bc8ab6 --><!-- begin field a92656ce-8465-4171-9f8f-acbc01590102 --><p>From age 12 years onwards (Female).</p><!-- end field a92656ce-8465-4171-9f8f-acbc01590102 --><!-- end item 723b09b8-6a5c-4247-b5bb-f04b82bc8ab6 -->","topic":{"id":"d4abfe41-b89f-5d51-8168-7ff98b4290f9","topicId":"4013d716-0ba5-4984-bfb1-8c7eca832ba8","topicName":"Menorrhagia","slug":"menorrhagia","lastRevised":"Last revised in December 2018","chapters":[{"id":"0e4b035a-9880-5848-b317-d92515f750d7","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"98c45e96-1179-53a4-9b74-a5f71fffaebd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"73a36e11-2419-5f1f-9d0a-989641466fbf","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"49315340-c2d5-5025-a18d-ab2347baae5b","slug":"changes","fullItemName":"Changes"},{"id":"a232dfd0-a500-5e6b-9ead-3c3c94f0d2cf","slug":"update","fullItemName":"Update"}]},{"id":"cdc50c06-ff06-509a-be3e-1047ea50bc07","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"e5043cba-12e2-5f47-aac7-4e74d516a7fa","slug":"goals","fullItemName":"Goals"},{"id":"b1ea37fe-6d24-5529-9f7e-c0e49ccba796","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cf03761e-6677-5ba5-ac47-f290b7cb66ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"24f740a2-df74-5305-b364-52d1fa68040a","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"913b3856-8846-53a2-86c7-f489c766e0f4","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"45c06974-d676-5c1e-bc8f-269a8c65df4f","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"7d698fba-d82e-55be-bcc0-0ee11398e628","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"aa066829-e43c-5a83-b602-2680d838463a","slug":"definition","fullItemName":"Definition"},{"id":"37436c25-6db1-5e7c-b8fd-7590cd5ca25d","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e5c102c5-46d5-5096-bb8b-d2ef0960e353","slug":"causes","fullItemName":"Causes"},{"id":"b7f926cd-7de3-5b25-9697-78920cccf7b7","slug":"complications","fullItemName":"Complications"}]},{"id":"305d1c2b-5b47-5eda-adc5-03782afe2229","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"fc278e0b-a1a4-54d5-b44c-ddde104596ea","slug":"assessment","fullItemName":"Assessment"},{"id":"1d41d3f0-3049-510f-982a-9d9c39c5d52f","slug":"investigations-for-the-cause-of-menorrhagia","fullItemName":"Investigations for the cause of menorrhagia"}]},{"id":"5c051ed4-4e95-59b7-8bf1-c9e426198f5f","fullItemName":"Management","slug":"management","subChapters":[{"id":"e30d2783-35fc-5470-9fb3-b8a643f83450","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"324cd8d0-2857-5c2b-bd8e-ac2d83c5b55d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c6b368dc-8409-55ee-8072-ffa3dc54a6f0","slug":"tranexamic-acid","fullItemName":"Tranexamic acid"},{"id":"13dd98d9-6054-5177-8564-df8c7ede9e5c","slug":"nonsteroidal-anti-inflammatory-drugs","fullItemName":"Nonsteroidal anti-inflammatory drugs"},{"id":"0e5ebc73-f73e-5d12-9e9a-82f8373fc507","slug":"oral-norethisterone","fullItemName":"Oral norethisterone"}]},{"id":"5964d183-6ca2-5e15-9a46-bd0c666e6146","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"443b20d0-895a-5b92-810b-17af26ab31e6","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"93531fdf-665e-5277-9d61-5b62984a866f","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"949f5d38-0e7a-59b8-a641-b1096ac7f3b3","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dd5aaa9a-b897-51a6-b133-d7e4170711df","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"81610614-c77a-5340-b5b3-721aafb19cc3","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"83d1c27f-0003-5757-b8a1-90f777106d61","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"8fe218e8-4e7d-55af-9b5b-4f2bad344402","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"5c051ed4-4e95-59b7-8bf1-c9e426198f5f","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"e31f4a63-bc90-5eee-aa82-90de887652f0","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 7167dc0b-14a7-4943-b5fb-a9ac0153004b --><h3>When should I refer a women with menorrhagia?</h3><!-- end field 7167dc0b-14a7-4943-b5fb-a9ac0153004b -->","summary":null,"htmlStringContent":"<!-- begin item 67a123ea-384b-4512-8438-a9ac0152ffa6 --><!-- begin field ae7dec58-731b-4e73-afb9-a9ac0153004b --><ul><li><strong>Refer the woman:</strong><ul><li><strong>U</strong><strong>rgently</strong> if physical examination identifies ascites and/or a pelvic or abdominal mass (which is not obviously due to uterine fibroids).</li><li><strong>Using a suspected cancer pathway referral</strong> (for an appointment within 2 weeks)<strong> </strong>if she has a pelvic mass associated with any other features of cancer (such as unexplained bleeding or weight loss). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gynaecological-cancers-recognition-referral/\">Gynaecological cancers - recognition and referral</a>.</li></ul></li><li><strong>Also refer if:</strong><ul><li>There are complications, such as compressive symptoms from large fibroids (for example dyspareunia, pelvic pain or discomfort, constipation, or urinary symptoms). For more information on when to refer women with fibroids, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/fibroids/management/management/\">Management of fibroids</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/fibroids/\">Fibroids</a>.</li><li>The woman has iron deficiency anaemia which has failed to respond to treatment, and other causes have been excluded. </li><li>Menorrhagia has not improved despite <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/management/management/#primary-care-management\">initial treatments</a>.</li></ul></li><li><strong>Consider referring </strong>women with fibroids of 3 cm or more in diameter to specialist care for additional investigations. For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/management/management/#primary-care-management\">Primary care management</a>. </li><li><strong>If pharmacological treatment is needed while the woman is awaiting treatment or referral appointment,</strong> offer <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/prescribing-information/tranexamic-acid/\">tranexamic acid</a> and/or a <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/prescribing-information/nonsteroidal-anti-inflammatory-drugs/\">non steroidal anti-inflammatory drug</a>. </li></ul><!-- end field ae7dec58-731b-4e73-afb9-a9ac0153004b --><!-- end item 67a123ea-384b-4512-8438-a9ac0152ffa6 -->","subChapters":[{"id":"83c22079-c225-560b-a6f8-9986ed3ec5d4","slug":"basis-for-recommendation-22b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f36452c2-7399-4683-9eec-a9ac01530063 --><h4>Basis for recommendation</h4><!-- end field f36452c2-7399-4683-9eec-a9ac01530063 -->","summary":null,"htmlStringContent":"<!-- begin item 22bd8008-7c70-45ce-809b-a9ac01530063 --><!-- begin field 63c32fe1-a68e-4788-8220-a9ac01530063 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Suspected cancer: recognition and referral </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2015</a>] and <em>Heavy menstrual bleeding: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2018</a>], the Institute of Obstetricians and Gynaecologists (IOG) guideline <em>The investigation and management of menorrhagia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">IOG, 2015</a>] and the British Medical Journal (BMJ) best practice guide <em>Dysfunctional uterine bleeding</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BMJ, 2017b</a>].</p><!-- end field 63c32fe1-a68e-4788-8220-a9ac01530063 --><!-- end item 22bd8008-7c70-45ce-809b-a9ac01530063 -->","subChapters":[]}]},{"id":"f475e2ce-6f1f-5b15-86d4-27d4d83d4041","slug":"primary-care-management","fullItemName":"Primary care management","depth":3,"htmlHeader":"<!-- begin field 7e0618ab-4b36-4d60-9d73-a9ac01584938 --><h3>How should I manage women with menorrhagia in primary care?</h3><!-- end field 7e0618ab-4b36-4d60-9d73-a9ac01584938 -->","summary":null,"htmlStringContent":"<!-- begin item b06b1bd9-a9e9-4f11-81f7-a9ac015847d3 --><!-- begin field ead7b130-7c8e-49d7-a9e7-a9ac01584938 --><ul><li><strong>Provide information on menorrhagia and its management. </strong><ul><li>Discuss the natural variability and range of menstrual blood loss with the woman. For some women, reassurance may be all that is required, and treatment may not be needed.</li><li>If the woman feels that she does not fall within the normal ranges, provide <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/management/management/#information-on-treatment-options\">information</a> on the possible treatment options and discuss these with the woman. Discussions should cover the benefits and risks of the various options, suitable treatments if she is trying to conceive, and whether she wants to retain her fertility and/or her uterus.</li><li>Provide written information, such as patient information leaflets, to explain the condition and treatment options.<ul><li>The NHS website (<a href=\"https://www.nhs.uk/\" data-hyperlink-id=\"80e219c9-06b8-472f-9270-a9ad00e84291\">www.nhs.uk</a>) has patient information on <a href=\"https://www.nhs.uk/conditions/heavy-periods/\" data-hyperlink-id=\"b9ebf1bd-64a5-4f92-9829-a9ad00e842af\">Heavy periods</a>.</li></ul></li></ul></li><li><strong>For women with no identified pathology, fibroids less than 3 cm in diameter, or suspected or diagnosed adenomyosis:</strong><ul><li>Consider a levonorgestrel intrauterine system (LNG-IUS) as the first-line treatment. For information on the LNG-IUS, including adverse effect, contraindications, and interactions, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-ius-iud/\">Contraception - IUS/IUD</a>. </li><li>If an LNG-IUS is declined or unsuitable, consider the following pharmacological treatments:<ul><li>Non-hormonal: <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/prescribing-information/tranexamic-acid/\">tranexamic acid</a> or a <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/prescribing-information/nonsteroidal-anti-inflammatory-drugs/\">non steroidal anti-inflammatory drug</a> (NSAID).</li><li>Hormonal: combined hormonal contraception (CHC) or a cyclical oral progestogen (such as <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/prescribing-information/oral-norethisterone/\">oral norethisterone</a>). For information on CHCs, including adverse effect, contraindications, and interactions, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a>.</li></ul></li><li>Be aware that progestogen-only contraception may suppress menstruation, which could be beneficial to women with menorrhagia. For information on progestogen-only contraception, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li><li>If treatment is unsuccessful, the woman declines pharmacological treatment, or symptoms are severe, consider referral to a specialist for:<ul><li>Investigations to diagnose the cause of menorrhagia, if needed, taking into account any <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/diagnosis/investigations-for-the-cause-of-menorrhagia/\">investigations</a> the woman has already had, <em>and</em></li><li>Alternative treatment choices, including pharmacological options not already tried and surgical options (second-generation endometrial ablation and hysterectomy). For women with submucosal fibroids, hysteroscopic removal may be considered. </li></ul></li></ul></li><li><strong>For women with fibroids of 3 cm or more in diameter, </strong>consider specialist referral for additional investigations and consideration of treatment options.<ul><li>If pharmacological treatment is needed while the woman is awaiting treatment or referral appointment, offer <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/prescribing-information/tranexamic-acid/\">tranexamic acid</a> and/or an <a class=\"topic-reference internal-reference\" href=\"/topics/menorrhagia/prescribing-information/nonsteroidal-anti-inflammatory-drugs/\">NSAID</a>. Advise women to continue using tranexamic acid and/or NSAIDs for as long as they are found to be beneficial. </li><li>Taking into account the size, location, and number of fibroids; the severity of the symptoms; the presence of any comorbidities; and the preference of the woman, secondary care treatment options for women with fibroids of 3 cm or more in diameter include:<ul><li>Pharmacological treatment — hormonal (LNG-IUS, CHC, or cyclical oral progestogens) or non-hormonal (NSAIDs or tranexamic acid).</li><li>Uterine artery embolization.</li><li>Surgery — myomectomy, hysterectomy, or second-generation endometrial ablation (considered for women with menorrhagia and fibroids of 3 cm or more in diameter who meet the criteria specified in the manufacturers' instructions).</li></ul></li></ul></li></ul><!-- end field ead7b130-7c8e-49d7-a9e7-a9ac01584938 --><!-- end item b06b1bd9-a9e9-4f11-81f7-a9ac015847d3 -->","subChapters":[{"id":"cbc19472-0f4e-5412-b2c5-5ff764d1aae6","slug":"information-on-treatment-options","fullItemName":"Information on treatment options","depth":4,"htmlHeader":"<!-- begin field 45cda98e-90ac-4040-8266-a9ad009115bc --><h4>Information on treatment options</h4><!-- end field 45cda98e-90ac-4040-8266-a9ad009115bc -->","summary":null,"htmlStringContent":"<!-- begin item 39f25099-9928-4628-9772-a9ad00911575 --><!-- begin field 46458dd5-223a-4d7c-aada-a9ad009115bc --><p><strong>Information on the treatment options for menorrhagia should be provided to (and discussed with) the woman and should cover the benefits and risks of the various options, suitable treatments if she is trying to conceive, and whether she wants to retain her fertility and/or her uterus.</strong></p><ul><li><strong>Levonorgestrel-releasing intrauterine system </strong><ul><li>Women should be informed:<ul><li>About anticipated changes in bleeding pattern, particularly in the first few cycles and maybe lasting longer than 6 months.</li><li>That it is advisable to wait for at least 6 cycles to see the benefits of the treatment.</li></ul></li></ul></li><li><strong>Uterine artery embolization (UAE)</strong><ul><li>UAE involves cannulating the femoral artery and identifying the uterine arteries before injecting an embolic agent into them to impair the blood supply to the uterus and fibroids (if present). </li><li>Women should be informed that UAE may potentially allow them to retain their fertility. </li></ul></li><li><strong>Myomectomy </strong><ul><li>Women should be informed that myomectomy may potentially allow them to retain their fertility. </li><li>Myomectomy may increase pregnancy rates compared with UAE in women with fibroids who wish to retain fertility.</li></ul></li><li><strong>Hysterectomy</strong><ul><li>The route of hysterectomy can be vaginal, abdominal, or laparoscopic. It may include removal or preservation of the ovaries, and/or removal or preservation of the cervix.</li><li>Women should be informed:<ul><li>About the increased risk of serious complications (such as intraoperative haemorrhage or damage to other abdominal organs) associated with hysterectomy when uterine fibroids are present.</li><li>About the risk of possible loss of ovarian function and its consequences, even if their ovaries are retained during hysterectomy.</li></ul></li><li>In all women who are considering hysterectomy, a full discussion should be had about the implications of surgery before a decision is made. The discussion should include:<ul><li>Psychological impact.</li><li>Alternative surgery.</li><li>The woman's expectations.</li><li>Treatment complications.</li><li>Need for further treatment.</li><li>Bladder function.</li><li>Impact on fertility.</li></ul></li></ul></li><li><strong>Endometrial ablation </strong><ul><li>Endometrial ablation involves destroying the endometrium (lining) and the superficial myometrium (muscle) of the uterus.</li><li>Women should be informed to avoid subsequent pregnancy and use effective contraception, if needed, after endometrial ablation. </li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">Haney, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">RCOG, 2013</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">BMJ, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2018</a>] </p><!-- end field 46458dd5-223a-4d7c-aada-a9ad009115bc --><!-- end item 39f25099-9928-4628-9772-a9ad00911575 -->","subChapters":[]},{"id":"cb5c445d-6ca2-53d7-bf5f-28b5e9af3458","slug":"basis-for-recommendation-246","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 953790b6-f2a8-4cdc-81c6-a9ac0158493a --><h4>Basis for recommendation</h4><!-- end field 953790b6-f2a8-4cdc-81c6-a9ac0158493a -->","summary":null,"htmlStringContent":"<!-- begin item 2463fb23-7d50-4167-8dea-a9ac0158493a --><!-- begin field 1bfc9dba-dc6a-44d1-8842-a9ac0158493a --><h5>Providing information</h5><ul><li>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Heavy menstrual bleeding: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2018</a>], the Institute of Obstetricians and Gynaecologists (IOG) guideline <em>The Investigation and management of menorrhagia</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">IOG, 2015</a>], and on what CKS considers to be good clinical practice.</li></ul><h5>Managing women with no identified pathology, fibroids less than 3 cm in diameter, or suspected or diagnosed adenomyosis</h5><ul><li>These recommendations are based on the NICE guideline <em>Heavy menstrual bleeding: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2018</a>]. For full details of the evidence and the NICE guideline development committee's discussion, see <a href=\"https://www.nice.org.uk/guidance/ng88/evidence/b-management-pdf-4782293102\" target=\"_top\" data-hyperlink-id=\"04bf1007-b8a6-485d-a11e-a9ad00f0eec4\">NICE evidence review B: management of heavy menstrual bleeding</a>.<ul><li>In current practice, the levonorgestrel intrauterine system (LNG-IUS) is a first-line treatment for menorrhagia in this group of women because evidence suggested that it is as effective as, or more effective than, other treatments in improving health-related quality of life and satisfaction with treatment. It also offered the best balance of benefits and costs.</li><li><strong>For women for whom the LNG-IUS is unacceptable or unsuitable,</strong> the NICE guideline development committee states that available evidence did not show clinically important differences in effectiveness and acceptability among the other pharmacological treatments, so there are several options that may be considered in this case. </li><li><strong>For women with severe symptoms and those for whom initial treatment is unsuccessful,</strong> the committee agreed that referral to specialist care may be considered because some women may benefit from further investigations (in particular those who started treatment without investigations) or from specialist management. There was a lack of evidence on second-line treatment, so a choice of pharmacological and surgical options can be considered.</li><li><strong>For women who decline pharmacological treatment and ask for surgery as a first treatment, </strong>the committee agreed that they may be referred to specialist care for consideration of further investigations and surgical treatment.<ul><li>The evidence showed that reduction in blood loss and satisfaction with treatment was greater for hysterectomy and second-generation endometrial ablation techniques than for first-generation endometrial ablation.</li><li>No evidence was found on hysteroscopic removal of submucosal fibroids, but the committee agreed that it is an effective treatment that is acceptable to many women. It can be done at the same time as diagnostic hysteroscopy if facilities are available.</li></ul></li></ul></li></ul><h5>Managing women with fibroids of 3 cm or more in diameter</h5><ul><li>These recommendations are based on the NICE guideline <em>Heavy menstrual bleeding: assessment and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/menorrhagia/references/\">NICE, 2018</a>]. For full details of the evidence and the NICE guideline development committee's discussion, see <a href=\"https://www.nice.org.uk/guidance/ng88/evidence/b-management-pdf-4782293102\" target=\"_top\" data-hyperlink-id=\"41d625d7-509a-4387-a186-a9ad00f0efcd\">NICE evidence review B: management of heavy menstrual bleeding</a>.<ul><li>The limited evidence identified by the NICE guideline development committee did not favour any one treatment over others for women with fibroids of 3 cm or more in diameter. However, the evidence for pharmacological treatment options was mainly for fibroids not substantially greater than 3 cm in diameter, whereas the evidence for interventional or surgical treatments was mainly for fibroids substantially greater than 3 cm in diameter.</li><li>The committee emphasized that it is importance to take the size, number, and location of fibroids as well as the severity of symptoms into account when considering treatment options, because:<ul><li>Women with fibroids that are substantially greater than 3 cm in diameter may benefit from more invasive treatment, such as uterine artery embolization or surgery. Therefore, referral to specialist care to discuss all treatment options with the woman should be considered.</li><li>Pharmacological treatment is not always the best option for fibroids that are substantially greater than 3 cm in diameter because of their physical effect on the uterine cavity. In addition, some women may prefer not to have pharmacological treatment. </li></ul></li><li>The committee also:<ul><li>Emphasized the importance of talking to the woman about her needs and preferences when deciding on treatments for menorrhagia, including any plans for pregnancy and whether she wants to retain her uterus or fertility.</li><li>Highlighted that the cause of menorrhagia and other symptoms should be taken into account to ensure that the most appropriate management strategy is offered to the woman.</li></ul></li></ul></li></ul><!-- end field 1bfc9dba-dc6a-44d1-8842-a9ac0158493a --><!-- end item 2463fb23-7d50-4167-8dea-a9ac0158493a -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}